These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16313323)

  • 21. Hepatitis C: ribavirin and/or interferon?
    Heathcote J
    Rev Gastroenterol Mex; 1996; 61(4 Suppl 2):S71-5. PubMed ID: 8986103
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of recurrent hepatitis C].
    Berenguer M
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():63-7. PubMed ID: 11968347
    [No Abstract]   [Full Text] [Related]  

  • 23. Cholestatic hepatitis due to hepatitis C virus after a living donor liver transplantation.
    Kaneko J; Sugawara Y; Akamatsu N; Kokudo N; Makuuchi M
    Hepatogastroenterology; 2004; 51(55):243-4. PubMed ID: 15011874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood eosinophilia after living donor liver transplantation for hepatitis C virus-related cirrhosis.
    Kishi Y; Sugawara Y; Kaneko J; Tamura S; Matsui Y; Makuuchi M
    Transplant Proc; 2007 Jun; 39(5):1540-3. PubMed ID: 17580184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of partial splenic artery embolization made it possible to administer interferon and ribavirin therapy in a liver transplant patient with fibrosing cholestatic hepatitis C complicated with thrombocytopenia.
    Sohara N; Takagi H; Kakizaki S; Sato K; Mori M
    Transpl Int; 2006 Mar; 19(3):255-7. PubMed ID: 16441778
    [No Abstract]   [Full Text] [Related]  

  • 27. The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
    Mindikoglu AL; Regev A; Casanova-Romero PY; Bejarano PA; Martinez EJ; Tzakis AG; Schiff ER
    Transplant Proc; 2006 Jun; 38(5):1440-4. PubMed ID: 16797327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indication for splenectomy in the era of living-donor liver transplantation.
    Jeng LB; Lee CC; Chiang HC; Chen TH; Hsu CH; Cheng HT; Lai HC
    Transplant Proc; 2008 Oct; 40(8):2531-3. PubMed ID: 18929791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients.
    Guo L; Orrego M; Rodriguez-Luna H; Balan V; Byrne T; Chopra K; Douglas DD; Harrison E; Moss A; Reddy KS; Williams JW; Rakela J; Mulligan D; Vargas HE
    Liver Transpl; 2006 Apr; 12(4):560-5. PubMed ID: 16555313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
    Sharma P; Marrero JA; Fontana RJ; Greenson JK; Conjeevaram H; Su GL; Askari F; Sullivan P; Lok AS
    Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.
    Wiesner RH; Sorrell M; Villamil F;
    Liver Transpl; 2003 Nov; 9(11):S1-9. PubMed ID: 14586888
    [No Abstract]   [Full Text] [Related]  

  • 32. New-onset diabetes mellitus after living donor liver transplantation: possible association with hepatitis C.
    Kishi Y; Sugawara Y; Tamura S; Kaneko J; Matsui Y; Makuuchi M
    Transplant Proc; 2006 Nov; 38(9):2989-92. PubMed ID: 17112882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of splenectomy or splenic artery ligation on the outcome of a living donor adult liver transplantation using a left lobe graft.
    Shimada M; Ijichi H; Yonemura Y; Harada N; Shiotani S; Ninomiya M; Terashi T; Yoshizumi T; Soejima Y; Suehiro T; Maehara Y
    Hepatogastroenterology; 2004; 51(57):625-9. PubMed ID: 15143878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating hepatitis C infection in liver transplant recipients.
    Terrault NA; Berenguer M
    Liver Transpl; 2006 Aug; 12(8):1192-204. PubMed ID: 16868944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of plasmapheresis therapy for perioperative management in ABO-incompatible adult living donor liver transplantation.
    Ashizawa T; Matsuno N; Yokoyama T; Kihara Y; Kuzuoka K; Taira S; Konno O; Jyojima Y; Akashi I; Nakamura Y; Hama K; Iwamoto H; Iwahori T; Nagao T; Kasahara M; Tanaka K
    Transplant Proc; 2006 Dec; 38(10):3629-32. PubMed ID: 17175351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C.
    Burra P
    Semin Liver Dis; 2009 Feb; 29(1):53-65. PubMed ID: 19235659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver function under interferon/ribavirin therapy of chronic hepatitis C.
    Stintzing S; Schmitt C; Ocker M; Ganslmayer M; Zopf S; Gahr S; Hahn EG; Herold C
    Hepatogastroenterology; 2009; 56(90):462-5. PubMed ID: 19579621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should splenectomy be performed for hepatitis C patients undergoing living-donor liver transplantation?
    Tashiro H; Itamoto T; Ohdan H; Fudaba Y; Kohashi T; Amano H; Ishiyama K; Takahashi S; Aikata H; Chayama K; Arihiro K; Asahara T
    J Gastroenterol Hepatol; 2007 Jun; 22(6):959-60. PubMed ID: 17565657
    [No Abstract]   [Full Text] [Related]  

  • 39. The natural history of hepatitis C cirrhosis after liver transplantation.
    Firpi RJ; Clark V; Soldevila-Pico C; Morelli G; Cabrera R; Levy C; Machicao VI; Chaoru C; Nelson DR
    Liver Transpl; 2009 Sep; 15(9):1063-71. PubMed ID: 19718647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers.
    Urbani L; Mazzoni A; Colombatto P; Bindi L; Biancofiore G; Tascini C; Menichetti F; Brunetto MR; Scatena F; Filipponi F
    Transplantation; 2008 Dec; 86(12):1666-71. PubMed ID: 19104402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.